Vertex Pharmaceuticals (NASDAQ: VRTX)
Vertex Pharmaceuticals Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Vertex Pharmaceuticals Company Info
Vertex is in the business of discovering, developing, and commercializing small-molecule drugs for the treatment of serious genetic diseases including cystic fibrosis.
News & Analysis
Biotech vs. Pharma: What's the Difference?
How to Invest in CRISPR Therapeutics Stock
Why This Biotech Company Could Be a Growth Stock Powerhouse
The stock has soared in the triple-digits over the past decade.
1 Reason Wall Street Is Obsessed With Vertex Pharmaceuticals
Here's why you can't find a Wall Street analyst who will tell you to sell this stock.
3 Absurdly Cheap Stocks to Buy for the Long Haul
They trade at some incredibly low earnings multiples.
The Best CRISPR Companies to Invest In
These CRISPR stocks could be big winners for patient investors.
Why This Biotech Company Could Be a Growth Stock Powerhouse
Recent developments aren't as devastating to the company's prospects as some might think.
Investing in the Best Healthcare Stocks
Valuation
Podcast Episodes
Alleged Industrial Espionage Makes an Interesting Story
We also chat about Vertex Pharmaceuticals and its role at the center of cystic fibrosis treatment.
3 Biotech Companies Analyzed
We examine three biotech companies' past performances and future outlooks.
Is Amarin's Fish Oil Pill on Track to Become a Blockbuster?
Plus, how gene-editing company CRISPR Therapeutics just took a big step forward.
Earnings Transcripts
Vertex Pharmaceuticals (VRTX) Q4 2024 Earnings Call Transcript
VRTX earnings call for the period ending December 31, 2024.
Vertex Pharmaceuticals (VRTX) Q3 2024 Earnings Call Transcript
VRTX earnings call for the period ending September 30, 2024.
Vertex Pharmaceuticals (VRTX) Q2 2024 Earnings Call Transcript
VRTX earnings call for the period ending June 30, 2024.
Vertex Pharmaceuticals (VRTX) Q1 2024 Earnings Call Transcript
VRTX earnings call for the period ending March 31, 2024.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.